“…The central substrate binding pocket is an obvious candidate site for binding of competitive inhibitors, because inhibitor binding sites overlapping with the S1 substrate site offer a straightforward structural mechanism for competitive inhibition and are in agreement with pharmacological data showing that competitive inhibitors can be displaced in a concentration-dependent manner by substrates (Talvenheimo et al, 1979;Humphreys et al, 1988;Marcusson and Tiger, 1988;Graham et al, 1989;Apparsundaram et al, 2008). Although mutational studies on the SLC6 NTTs have identified residues in virtually all TM domains to be important for recognition of competitive inhibitors, the majority of the most sensitive residues reside within the regions that form the extracellular permeation pathway and the S1 substrate binding pocket (Barker et al, 1994(Barker et al, , 1998Barker and Blakely, 1996;Mortensen et al, 1999;Adkins et al, 2001;Larsen et al, 2004;Henry et al, 2006b;Beuming et al, 2008;Severinsen et al, 2008;Walline et al, 2008;Andersen et al, 2009bAndersen et al, , 2010Field et al, 2010). For example, in the monoamine transporters, sensitivity toward a wide range of competitive inhibitors, including fluoxetine, paroxetine, citalopram, and imipramine, as well as psychostimulants such as cocaine and amphet- THE SLC6 NEUROTRANSMITTER TRANSPORTERS amines, can be decreased by several orders of magnitude by mutation of S1 residues (Barker et al, 1999;Henry et al, 2006b;Beuming et al, 2008;Walline et al, 2008;Andersen et al, 2009bAndersen et al, , 2010Koldsø et al, 2010;Sinning et al, 2010).…”